Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
The latest announcement is out from Lexaria Bioscience ( (LEXX) ).
Lexaria Bioscience Corp. announced a $2 million registered direct offering of common stock, involving the sale of 2,000,000 shares at $1.00 each to a single institutional investor. The proceeds from this offering, facilitated by H.C. Wainwright & Co., are intended for working capital and general corporate purposes, potentially enhancing Lexaria’s operational capabilities and market positioning.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, known for its patented DehydraTECH technology that enhances the oral delivery of drugs by improving bio-absorption and reducing side effects. The company operates a licensed in-house research laboratory and holds a significant intellectual property portfolio with 48 granted patents worldwide.
YTD Price Performance: -26.52%
Average Trading Volume: 96,516
Technical Sentiment Signal: Buy
Current Market Cap: $29.68M
Learn more about LEXX stock on TipRanks’ Stock Analysis page.